Navigation Links
Biomoda Appoints Three Business Leaders to Board of Directors

New members will help commercialize innovative technologies for early lung

cancer detection

ALBUQUERQUE, N.M., May 5 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (, a development stage medical diagnostics company, today announced the election of three business leaders, Maria Zannes, David Lambros, and Lewis White, to its Board of Directors. The Board Members' terms as Directors began May 1.

"We are pleased to engage these leaders' keen business expertise and apply their high levels of practical and regulatory experience in the interests of Biomoda shareholders," said John Cousins, Biomoda president. "With their involvement, Biomoda is in an ideal position to influence the future of technology for early diagnosis and treatment of lung cancer throughout the world."

-- Maria Zannes brings more than 25 years of experience in the

environmental and energy industry -- from federal lobbyist to company

president. Formerly the president of the national waste-to-energy

trade group in Washington, D.C., Zannes currently consults for private

clients in the medical and waste industry. She was a legislative aide

and press secretary to Congressman Charles Wilson (D-Texas) after

leaving her home state of New Mexico where she began her career as a

journalist. Zannes is licensed to practice law in Washington State and

will be sworn into practice in New Mexico this summer

-- David Lambros was the elected law director of Brook Park, Ohio, and

presently serves the law director of the Village of Valley View and

the Village of Kelleys Island, Ohio. As law director, he served as the

chief legal counsel to cities negotiating with corporations and

business, and is an expert in municipal law. Lambros has practiced law

for more than 25 years and served on various boards, including

Commerce Exchange Bank and Southwest General Hospital. As a board

member of Commerce Exchange Bank, he was instrumental in raising share

value of the stock from $2.00 to a sale price of $13.00. He presently

is a director on the Systems Board at Southwest General Hospital, a

multi-million dollar company.

-- Lewis White, a major shareholder in Biomoda, is director and CEO of

New Energies Nebraska, LLC, a subsidiary of Standard Alcohol Company.

He has also served as CEO of Los Hojas Corporation and owned a

successful childcare business for 20 years, which he followed with an

interest in business investment through real estate and a thriving

food services business catering to niche markets. White attended the

University of Nebraska at Omaha where majored in Business

Administration and worked for the State of Nebraska.

With Biomoda's technology, clinicians can identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected under a microscope. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease at more advanced stages. Biomoda's technology complements these tools by screening for signs of lung cancer at an earlier stage, ensuring that patients receive advanced tests at the appropriate time.

Earlier this year, Biomoda and the New Mexico Institute of Mining and Technology announced their partnership with the New Mexico Department of Veterans Services to conduct a $350,000 clinical study using Biomoda's proprietary testing technology for detection of early lung cancer in the state's veterans. The New Mexico state legislature recently allocated an additional $1.3 million in funding through the Interim Tobacco Settlement Committee to the clinical screening program.

Lung cancer claims more lives than any other cancer. The expected five-year survival rate for all patients diagnosed with lung cancer is 15 percent; the five-year survival rate for cases detected when the disease is still localized is 50 percent. Presently, only 16 percent of lung cancer cases are diagnosed at this early stage.
Biomoda's technology was originally developed at Los Alamos National


For more information contact:

John Cousins

Biomoda, Inc.


Forward-Looking Statement

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Biomoda's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. Biomoda, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Biomoda's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Announces Upcoming Interview With CEO of Biomoda
2. Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts
3. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
4. Biomoda Announces Collaborative Agreement With New Mexico Tech
5. Biomoda Hires Senior Scientist to Expand Research & Development Effort
6. Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans
7. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
8. Codexis Appoints Singapore Laboratories Managing Director
9. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
Breaking Biology Technology:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Capacitive Fingerprint Sensors - Technology and ... --> --> ... market, especially in smartphones. The fingerprint sensor vendor Idex ... fingerprint sensor units in mobile devices and of the ...
(Date:11/20/2015)... 20, 2015 NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... , was recently interviewed on The RedChip Money ... this weekend on Bloomberg Europe , Bloomberg Asia, ... --> NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:11/19/2015)... Nov. 19, 2015  Based on its in-depth analysis ... recognizes BIO-key with the 2015 Global Frost & Sullivan ... & Sullivan presents this award to the company that ... the needs of the market it serves. The award ... and expands on customer base demands, the overall impact ...
Breaking Biology News(10 mins):